menu
    • menu

    Company profile for Avacta Therapeutics

    NEW Drugs in Dev: 1
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Avacta is a clinical stage biotechnology company expanding the reach of highly potent cancer therapies with the pre|CISION? platform.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Avacta Therapeuticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Scale Space, White City Imperial College Campus 58 Wood Lane London
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://avacta.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/avacta/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Avacta Presents Pre|Cision Candidates At 2026 AACR Conference
    Avacta Presents Pre|Cision Candidates At 2026 AACR Conference

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3256882/0/en/Avacta-Announces-Preclinical-and-Translational-Presentations-of-pre-CISION-Platform-Candidates-at-the-2026-AACR-Annual-Conference.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Avacta Appoints Francis Wilson As Chief Scientific Officer
    Avacta Appoints Francis Wilson As Chief Scientific Officer

    09 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/09/3234244/0/en/Avacta-appoints-Francis-Wilson-as-Chief-Scientific-Officer.html

    GLOBENEWSWIRE
    09 Feb 2026
    Share Share
    Avacta Reveals Dual Clinical Advancements In Faridoxorubicin
    Avacta Reveals Dual Clinical Advancements In Faridoxorubicin

    03 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/03/3230915/0/en/Avacta-Announces-Two-Key-Clinical-Updates-to-its-Faridoxorubicin-Program.html

    GLOBENEWSWIRE
    03 Feb 2026
    Share Share
    FDA Clears Avacta's IND Application for AVA6103 (FAP-Exatecan)
    FDA Clears Avacta's IND Application for AVA6103 (FAP-Exatecan)

    21 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/21/3222755/0/en/Avacta-Announces-U-S-Food-and-Drug-Administration-Clearance-of-the-Investigational-New-Drug-IND-Application-for-the-Second-pre-CISION-Medicine-FAP-Exatecan-AVA6103.html

    GLOBENEWSWIRE
    21 Jan 2026
    Share Share
    Avacta Announces Year-End Trading Update
    Avacta Announces Year-End Trading Update

    20 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/20/3221535/0/en/Avacta-Announces-Year-end-Trading-Update.html

    GLOBENEWSWIRE
    20 Jan 2026
    Share Share
    AVA6000 Phase 1b Trial Shows Tumor Shrinkage in Salivary Cancers
    AVA6000 Phase 1b Trial Shows Tumor Shrinkage in Salivary Cancers

    17 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/17/3206840/0/en/Faridoxorubicin-AVA6000-Phase-1b-cohort-demonstrates-clinically-meaningful-tumor-shrinkage-in-patients-with-salivary-gland-cancers.html

    GLOBENEWSWIRE
    17 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search